Stocks in play: BriaCell Therapeutics Corp.
Announced that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp., a wholly-owned subsidiary of the Company pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCd) inhibitors for multiple indications including cancer, will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act (British Columbia). “As we focus our efforts on the upcoming pivotal study of our lead clinical candidate, Bria-IMT™, in advanced metastatic breast cancer, we believe that this strategy of spinning out certain pre-clinical immunotherapies in a separate entity of BriaPro Therapeutics Corp. will position them for success and will create our shareholders value over the long term,” stated Dr. William V. Williams, BriaCell’s President and CEO. “We continue with our mission to develop novel immunotherapies to fight cancer and improve patients’ lives whose medical needs are currently unmet.” BriaCell Therapeutics Corp. shares T.BCT are trading off 29 cents at $8.19.
Read:
Global Lithium Supply Under Pressure as South American Nations Discuss "Lithium OPEC"
International Lithium Buyers Looking to South America to Fill Supply Gaps
Race to Secure Critical EV Battery Metals Ahead of Chinese Dominance Fully Underway
Help is on the Way as Rising Alzheimer’s Cases Highlight Urgency for New Treatments
FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023